Vimarsana
Biggest News Aggregation in the World

Demonstrated Deep News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Demonstrated Deep. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Demonstrated Deep Today - Breaking & Trending Today

Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study - Vimarsana News

Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study

Published: June 5, 2023

First analysis data from CARTITUDE-4 demonstrated a statistically significant improvement in progression-free survival, with a hazard ratio of 0.26 CARTITUDE-4 is the first randomized study... | June 5, 2023

Source: marketscreener.com
Related Topics:
New JerseyUnited StatesHemophagocytic LymphohistiocytosisEuropean Hematology AssociationJanssen Biotech IncMedicinal Devices AgencyLegend Biotech CorporationAmerican Society Of Clinical OncologyExchange Commission OnDrug AdministrationCommunity Register Of Orphan Medicinal ProductsJapan Ministry Of HealthAmerican Society Of Oncology Annual MeetingCongress AbstractEuropean CommissionAmerican Cancer SocietyEuropean Commission For The Treatment Of PatientsLegend BiotechNew England JournalHematology AssociationHybrid CongressDemonstrated DeepYear Follow Up DataJanssen BiotechImportant Safety
Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study - Vimarsana News

Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study

Published: June 5, 2023

05.06.2023 - Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that results from the Phase 3 CARTITUDE-4 ...

Source: wallstreet-online.de
Related Topics:
United StatesNew JerseyMythili KoneruHemophagocytic LymphohistiocytosisBinod DhakalExchange Commission OnJanssen Biotech IncJapan Ministry Of HealthEuropean Hematology AssociationAmerican Society Of Clinical OncologyDrug AdministrationAmerican Society Of Oncology Annual MeetingEuropean Commission For The Treatment Of PatientsAmerican Cancer SocietyCollege Of WisconsinLegend Biotech Corporation StockDivision Of HematologyEuropean CommissionMedicinal Devices AgencyCommunity Register Of Orphan Medicinal ProductsAssociate ProfessorMedical CollegeChief Medical OfficerDemonstrated DeepYear Follow Up Data